Last reviewed · How we verify
NCT06881537
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Phase 2 trial testing Capecitabine in Locally Recurrent Colorectal Cancer in 15 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 June 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Capecitabine (capecitabine) — full drug profile →
- Oxaliplatin (Oxaliplatin) — full drug profile →
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Tislelizumab (TISLELIZUMAB) — full drug profile →
Conditions studied
- Locally Recurrent Colorectal Cancer — all drugs for Locally Recurrent Colorectal Cancer →
Sponsor
Shanghai Changzheng Hospital
Who can join
Adults 18 to 75, any sex, with Locally Recurrent Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06881537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capecitabine
Trials testing the same drug.
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer · Phase 3 · not yet recruiting
- NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06881537 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06881537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing